Podcast: Navigating IND Applications & Pre-IND Meetings: Key Considerations And Misconceptions

Generate a summary of this article
Listen to this article
Beta
  

Advancing Investigational New Drugs (INDs) can be a complex process, especially for smaller companies. Listen to your free podcast now as Marcus Delatte, PhD, Vice President at Allucent and Harshini Neelakantan, Executive Director at Ridgeline Therapeutics discuss best practices and considerations for leveraging your pre-IND meeting and submitting a successful IND application.

Listen now for insights into:

  • Current trends and challenges related to IND submissions
  • The purpose and benefits of pre-IND meetings with regulatory bodies
  • Indicators that should prompt companies to request a pre-IND meeting
  • The role of consultants in supporting sponsors in pre-IND meetings
  • Getting the most from your pre-IND meeting and tips for IND application success
  • How IND submissions will evolve in the future

Citeline · Navigating IND Applications & Pre-IND Meetings: Key Considerations And Misconceptions

Citeline · Navigating IND Applications & Pre-IND Meetings: Key Considerations And Misconceptions

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Archive

Optimizing Drug Pipelines With Biophysical Methods

Optimizing Drug Pipelines With Biophysical Methods”, your view into how using biophysical techniques can enhance and streamline processes throughout the drug discovery and validation cycle.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

GSK Looks To Catch Up In mRNA Vaccines With New CureVac Deal

 
• By Andrew McConaghie

GSK will assume full control of mRNA shots in infectious disease, allowing CureVac to cut costs and pivot its research to oncology.

More from Scrip

Sponsored by :

Clinical Trial Complexity Is Reshaping Evidence Collection Clinical trial innovation has historical - Clone

As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.

Sponsored by :

Clinical Trial Complexity Is Reshaping Evidence Collection Clinical trial innovation has historical

As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.

Primal Pictures

GB-Business-Free: ‘Content’ article that includes different Composer content published on 4 Dec after the BIOME redeployment...

To make your document look professionally produced, Word provides header, footer, cover page, and text box designs that complement each other. For example, you can add a matching cover page, header, and sidebar. Click Insert and then choose the elements you want from the different galleries.